134 related articles for article (PubMed ID: 38262251)
21. Radiofrequency ablation for treatment of locally recurrent thyroid cancer presenting as a metastatic lymph node with dense macrocalcification: A case report and literature review.
Yoo RE; Kim JH; Paeng JC; Park YJ
Medicine (Baltimore); 2018 Mar; 97(9):e0003. PubMed ID: 29489641
[TBL] [Abstract][Full Text] [Related]
22. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
[TBL] [Abstract][Full Text] [Related]
23. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
Vassilopoulou-Sellin R; Schultz PN; Haynie TP
Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
[TBL] [Abstract][Full Text] [Related]
24. Recurrent Papillary Thyroid Carcinoma to the Cervical Lymph Nodes: Outcomes of Compartment-Oriented Lymph Node Resection.
Rivera-Robledo CG; Velázquez-Fernández D; Pantoja JP; Sierra M; Pérez-Enriquez B; Rivera-Moscoso R; Chapa M; Herrera MF
World J Surg; 2019 Nov; 43(11):2842-2849. PubMed ID: 31372725
[TBL] [Abstract][Full Text] [Related]
25. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
[TBL] [Abstract][Full Text] [Related]
26. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
[TBL] [Abstract][Full Text] [Related]
27. High-dose radioactive iodine therapy is associated with decreased risk of recurrence in high-risk papillary thyroid cancer.
Gray KD; Bannani S; Caillard C; Amanat S; Ullmann TM; Romanov P; Brunaud L; Beninato T; Fahey TJ; Mirallie E; Zarnegar R
Surgery; 2019 Jan; 165(1):37-43. PubMed ID: 30274732
[TBL] [Abstract][Full Text] [Related]
28. Low-risk papillary thyroid cancer recurrence in patients treated with total thyroidectomy and adjuvant therapy vs. patients treated with partial thyroidectomy.
Hurtado-López LM; Melchor-Ruan J; Basurto-Kuba E; Montes de Oca-Durán ER; Pulido-Cejudo A; Athié-Gutiérrez C
Cir Cir; 2011; 79(2):118-25. PubMed ID: 21631972
[TBL] [Abstract][Full Text] [Related]
29. Routine prophylactic central neck dissection for low-risk papillary thyroid cancer is not cost-effective.
Garcia A; Palmer BJ; Parks NA; Liu TH
Clin Endocrinol (Oxf); 2014 Nov; 81(5):754-61. PubMed ID: 24862564
[TBL] [Abstract][Full Text] [Related]
30. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
[TBL] [Abstract][Full Text] [Related]
31. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
[TBL] [Abstract][Full Text] [Related]
32. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification.
Nixon IJ; Ganly I; Patel SG; Palmer FL; Di Lorenzo MM; Grewal RK; Larson SM; Tuttle RM; Shaha A; Shah JP
Thyroid; 2013 Jun; 23(6):683-94. PubMed ID: 23742290
[TBL] [Abstract][Full Text] [Related]
33. Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma: All Risks, No Reward.
Dismukes J; Fazendin J; Obiarinze R; Márquez GCH; Ramonell KM; Buczek E; Lindeman B; Chen H
J Surg Res; 2021 Aug; 264():230-235. PubMed ID: 33838407
[TBL] [Abstract][Full Text] [Related]
34. Recurrence after low-dose radioiodine ablation and recombinant human thyroid-stimulating hormone for differentiated thyroid cancer (HiLo): long-term results of an open-label, non-inferiority randomised controlled trial.
Dehbi HM; Mallick U; Wadsley J; Newbold K; Harmer C; Hackshaw A
Lancet Diabetes Endocrinol; 2019 Jan; 7(1):44-51. PubMed ID: 30501974
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of prophylactic central compartment neck dissection in the treatment of clinically node-negative papillary thyroid cancer patients.
Gambardella C; Tartaglia E; Nunziata A; Izzo G; Siciliano G; Cavallo F; Mauriello C; Napolitano S; Thomas G; Testa D; Rossetti G; Sanguinetti A; Avenia N; Conzo G
World J Surg Oncol; 2016 Sep; 14(1):247. PubMed ID: 27644091
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
[No Abstract] [Full Text] [Related]
37. Association of tumor size and focality with recurrence/persistence in papillary thyroid cancer patients treated with total thyroidectomy along with radioactive-iodine ablation and TSH suppression.
Khan M; Syed AA; Khan AI; Hussain SR; Urooj N
Updates Surg; 2018 Mar; 70(1):121-127. PubMed ID: 28550398
[TBL] [Abstract][Full Text] [Related]
38. Predictors for papillary thyroid cancer persistence and recurrence: a retrospective analysis with a 10-year follow-up cohort study.
de Castro TP; Waissmann W; Simões TC; de Mello RC; Carvalho DP
Clin Endocrinol (Oxf); 2016 Sep; 85(3):466-74. PubMed ID: 26834009
[TBL] [Abstract][Full Text] [Related]
39. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
[TBL] [Abstract][Full Text] [Related]
40. Predictive value of nodal metastases on local recurrence in the management of differentiated thyroid cancer. Retrospective clinical study.
Conzo G; Docimo G; Pasquali D; Mauriello C; Gambardella C; Esposito D; Tartaglia E; Della Pietra C; Napolitano S; Rizzuto A; Santini L
BMC Surg; 2013; 13 Suppl 2(Suppl 2):S3. PubMed ID: 24267409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
